within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DH52_MeropenemAndVaborbactam;

model MeropenemAndVaborbactam
  extends Pharmacolibrary.Drugs.ATC.J.J01DH52;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01DH52</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Meropenem and vaborbactam is a combination antibacterial drug consisting of meropenem, a broad-spectrum carbapenem antibiotic, and vaborbactam, a β-lactamase inhibitor. This combination is used for the treatment of complicated urinary tract infections, including pyelonephritis, caused by susceptible Gram-negative bacteria. The combination is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are described for healthy adult subjects (average age ~35 years, both sexes) after intravenous administration.</p><h4>References</h4><ol><li><p>Rubino, CM, et al., &amp; Griffith, DC (2018). Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment. <i>Antimicrobial agents and chemotherapy</i> 62(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02103-17\">10.1128/AAC.02103-17</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29311069/\">https://pubmed.ncbi.nlm.nih.gov/29311069</a></p></li><li><p>Zhuang, L, et al., &amp; Wang, Y (2020). Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation. <i>Journal of clinical pharmacology</i> 60(8) 1011–1021. DOI:<a href=\"https://doi.org/10.1002/jcph.1595\">10.1002/jcph.1595</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32149406/\">https://pubmed.ncbi.nlm.nih.gov/32149406</a></p></li><li><p>Volpicelli, L, et al., &amp; Oliva, A (2024). Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin. <i>Journal of global antimicrobial resistance</i> 37 86–90. DOI:<a href=\"https://doi.org/10.1016/j.jgar.2024.03.003\">10.1016/j.jgar.2024.03.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38519025/\">https://pubmed.ncbi.nlm.nih.gov/38519025</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MeropenemAndVaborbactam;
